FDA granted Priority Review for defibrotide for the treatment of patients with hepatic veno-occlusive disease, also known as sinusoidal obstruction syndrome, with evidence of multi-organ dysfunction following hematopoietic stem-cell transplantation.
Peer review, registries, and evidence-based patient information have taken a hit in Trump’s first 100 days in office.
